Urothelial and immune-cell inflammatory response

The urothelial and immune-cell inflammatory response is a complex physiological process rather than a single molecular target (Birder & Andersson, 2013) [1]. It involves the activation of the urothelium, the specialized epithelial lining of the urinary tract, which acts as a sensor for chemical, mechanical, and microbial stimuli (Hurst et al., 2014) [2]. Upon activation, urothelial cells release various mediators, including ATP and cytokines, which recruit and activate immune cells such as mast cells and macrophages in the bladder wall (Gonzalez et al., 2014) [3]. This interaction creates a pro-inflammatory microenvironment that contributes to the pathogenesis of conditions like interstitial cystitis and bladder pain syndrome [1]. Chronic activation of this response leads to urothelial barrier dysfunction, sensory nerve sensitization, and persistent pain [2]. Because it encompasses a broad network of signaling events, therapeutic strategies focus on specific molecular components within the pathway, such as cytokine receptors or ion channels, to modulate the overall inflammatory state [3]. Drugs like pentosan polysulfate sodium aim to restore the urothelial barrier, while others like hydroxyzine target the immune component by stabilizing mast cells [4, 6].

Other names

Urothelial-immune crosstalkBladder inflammatory cascadeUrothelial inflammatory signalingUrothelial-mediated inflammation

Pharmacological agents modulate this response by stabilizing mast cells, inhibiting histamine release, restoring the protective glycosaminoglycan layer of the urothelium, or suppressing T-cell mediated inflammation.